Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results (S56.003)

Conclusions:A significant reduction in UDysRS total score was seen at Week 12 in the pooled analysis, which was driven by an effect on both the historical (patient-reported) and objective (physician-assessed) scores.Study Supported by:This study was sponsored by Adamas Pharmaceuticals, Inc.Disclosure: Dr. Pahwa has received personal compensation for activities with AbbVie, ACADIA, Acorda, Adamas, Cynapses, Global Kinetics, Lundbeck, Neurocrine, Pfizer, Sage, Teva Neuroscience and US World Meds as a consultant. Dr. Pahwa has received personal compensation in an editorial capacity for the International Journal of Neuroscience. Dr. Pahwa has received research support from AbbVie, Adamas, Avid, Biotie, Boston Scientific, Civitas, Cynapses, Kyowa, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group, and Pfizer. Dr. Tanner has received personal compensation for activities with Adamas, Neurocrine, Ultragenyx Pharmaceuticals, Cynapsus Pharmaceuticals, Biotie Pharmaceuticals, and INTEC Pharma as a consultant or a data monitoring service member. Dr. Hauser has received personal compensation for activities with Guidepoint Global, SAI-Mmed Partners, Scienomics Group, Gerson Lehrman Group, LCN Consulting, Putnam Associates, National Parkinson Foundation, eResearch Technology, Inc., Lundbeck LLC, Krog & Partners, and Cynapsus as a consultant. Dr. Hauser has received licensing fee payments from the University of South Florida. Dr. Hauser has received research support from Ab...
Source: Neurology - Category: Neurology Authors: Tags: Movement Disorders: Huntington ' s Disease and Drug-Induced Dyskinesias Source Type: research